Axsome Therapeutics (AXSM) Gains Buy Rating Amid Smoking Cessation Trial, But Valuation Remains Elevated

gurufocus.com · 2026-08-31

On August 31, 2026, H.C. Wainwright reaffirmed its Buy rating on Axsome Therapeutics Inc (NASDAQ: AXSM) and set a price target of $290 following the company's a

Read the full story at gurufocus.com →